Hence, it is imperative to understand the ChREBP-mediated transcriptional control of glycolytic and lipogenic gene expression in order to develop novel strategies for treatment and prevention of hepatic insulin resistance and T2DM [37]. The gene discussed is MLXIPL; the disease is type 2 diabetes mellitus.